Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company, specializes in the emerging field of molecular medicine. The company is committed to applying innovations in the identification and targeting of disease to enhance patient healthcare by treating significant, but unmet medical needs. Their focus is on discovering, developing and commercializing novel radiotherapeutics and molecular imaging pharmaceuticals for initial application in the areas of oncology and cardiology. For further information, visit the Company’s web site at www.molecularinsight.com.
- 17 years ago
QualityStocks
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Files NI 43-101 Technical Report Supporting Swanson Gold Project PEA
This article has been disseminated on behalf of LaFleur Minerals and may include paid advertising.…
-
LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Executives Outline Positive PEA Results Plus Company’s Next Steps to Production in Investor Webinar
Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid…
-
Versus Systems Inc. (NASDAQ: VS) Is ‘One to Watch’
Versus Systems operates a patented earned-rewards platform that integrates gamification with real-world incentives across digital…